Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Carcinoma, Non-Small-Cell Lung 307Lung Neoplasms 111Pancreatic Neoplasms 70Neoplasms 56Neoplasm Metastasis 32Brain Neoplasms 31Head and Neck Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Glioblastoma 24Adenocarcinoma of Lung 23Gliosarcoma 22Non-Squamous Non-Small Cell Lung Cancer 21Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Adenocarcinoma, Bronchiolo-Alveolar 16Rectal Neoplasms 13Colonic Neoplasms 13Carcinoma, Renal Cell 13Glioma 12Esophageal Neoplasms 11Astrocytoma 11Central Nervous System Neoplasms 9Carcinoma, Squamous Cell 9Salivary Gland Neoplasms 8Prostatic Neoplasms 8Oligodendroglioma 8Gallbladder Neoplasms 8Adenocarcinoma 8Ovarian Neoplasms 7

Interventions

Carboplatin 12Paclitaxel 11Gemcitabine 11Capecitabine 7Irinotecan 6Fluorouracil 5Cisplatin 5Radiotherapy 4Oxaliplatin 4Leucovorin 4Bevacizumab 4pembrolizumab 3Filgrastim 3Etoposide 3Erlotinib Hydrochloride 3Cyclophosphamide 3etoposide phosphate 2atezolizumab 2Trastuzumab 2Topotecan 2Taxes 2Surveys and Questionnaires 2Peripheral Blood Stem Cell Transplantation 2Magnetic Resonance Spectroscopy 2Genetic Testing 2FAPI-46 2Docetaxel 2CP protocol 2Amifostine 2Albumin-Bound Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms, Unknown Primary × Erlotinib Hydrochloride × Clear all
NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00360360 2013-12-04

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
60 enrolled 6 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00193622 2010-09-17

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡